The clinical use of plasma clozapine levels

References

• Kane J, Honigfeld G, Singer J, Meltzer H Y. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45: 789–796
   PubMed Web of Science ®Google Scholar
• Copolov D L, Bell W R, Benson W J, Keks N A, Strazzeri D C, Johnson G F. Clozapine treatment in Australia—a review of haematological monitoring. Medical Journal of Australia 1997; 168: 495–497
   Google Scholar
• Gelenberg A J. Clozapine-induced agranulocytosis and seizures. Biology of Therapeutic Psychiatry 1989; 12: 2–3
   Google Scholar
• Ackenheil V, Brau H, Burkhart A, Franke A, Pacha W. Antipsychotische Wirksamkeit im Verhälnis zum Plasmaspiegel von Clozapin (Antipsychotic efficacy in relation to plasma levels of clozapine). Arzneimittelforschung 1976; 26: 1156–1158
   Google Scholar
• Thorup M, Fog R. Clozapine treatment of schizophrenic patients: plasma concentrations and coagulation factors. Acta Psychiatrica Scandinavica 1977; 55: 123–126
   Google Scholar
• Brau H, Burkhart A, Pacha W, Ackenheil V. Benziehungen zwischen Wirkungen und Plasmaspiegel von Clozapin (Relationships between effects and plasma levels of cloza pine). Arzneimitteljorschung 1978; 28: 1300
   Google Scholar
• Perry P J, Miller D D, Amdt S V, Cadoret R J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. American Journal of Psychiatry 1991; 148: 231–235
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer H Y. Relationship between clinical efficacy and clozapine con centrations in plasma in schizophrenia: effect of smoking. Journal of Clinical Psychopharmacology 1993; 13: 383–390
   PubMed Web of Science ®Google Scholar
• Potkin S G, Bera R, Gulasekararn B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry 1994; 55(Suppl. B)133–136
   PubMed Web of Science ®Google Scholar
• Miller D D, Fleming F, Holman T L, Perry P J. Plasma cloza pine concentrations as a predictor of clinical response: a follow-up study. Journal of Clinical Psychiatry 1994; 55(Suppl.B)117–121
   Google Scholar
• Kronig M H, Munne R A, Szymanski S, et al. Plasma cloza pine levels and clinical response for treatment-refractory schizophrenic patients. American Journal of Psychiatry 1995; 152: 179–182
   PubMed Web of Science ®Google Scholar
• Vander Zwaag C, McGee M, McEvoy J P, et al. Response of patients with treatment-refractory schizophrenia to cloza pine within three plasma level ranges. American Journal of Psychiatry 1996; 153: 1579–1584
   Google Scholar
• Pirmohamed M, Williams D, Madden S, Templeton E, Park B K. Metabolism and bioactivation of clozapine by human liverin vitro. Journal of Pharmacology and Experimental Therapeutics 1995; 272: 984–990
   PubMed Web of Science ®Google Scholar
• Rosenthal J., Nimmerfall F, Sigrist R, et al. Non-equilibrium method for the radioimmuno-assay of clozapine in the preaence of metabolites. European Journal of Biochemistry 1977; 80: 603–609
   Google Scholar
• Fisher V, Vogels B., Maurer G, et al. The antipsychotic clozapine is metabolised by the polymorphic human microsomal and recombinant cytochrome P450 2D6. Journal of Pharmacology and Experimental Therapeutics 1992; 260: 1355–1360
   Google Scholar
• Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring 1994; 16: 368–374
   PubMed Web of Science ®Google Scholar
• Haring C, Meise U, Humpel C, et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989; 99: S38–40
   PubMed Web of Science ®Google Scholar
• Baldessarini R J, Frankenburg F R. Clozapine: a novel antipsychotic agent. New England Journal of Medicine 1991; 324: 746–54
   PubMed Web of Science ®Google Scholar
• Haring C, Fleischhacker W W, Schett P, Humpel C, et al. Influence of patient-related variables on clozapine plasma levels. American Journal of Psychiatry 1990; 147: 1471–1475
   PubMed Web of Science ®Google Scholar
• Oyewumi L K, Freeman D J, Vollick D. Can low-dose cloza pine pharmacokinetics predict steady-state plasma concentration?. Therapeutic Drug Monitoring 1995; 17: 137–141
   Google Scholar
• Centorrino F, Baldessarini R J, Kando J C, et al. Clorapine and metabolites: concentrations in plasma and clinical findings during treatment of chronically psychotic patients. Journal of Clinical Psychopharmacology 1994; 14: 119–125
   PubMed Web of Science ®Google Scholar
• Chung M-C, Lin S-K, Chang W-H. Determination of cloza pine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography 1993; 613: 168–173
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini R J, Kando J, et al. Plasma con centrations of clozapine and its major metabolites: effects of co-treatment with fluoxetine or valproate. American Journal of Psychiatry 1994; 151: 123–125
   PubMed Web of Science ®Google Scholar
• Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. Journal of Clinical Psychiatry 1996; 57: 12–35
   PubMed Web of Science ®Google Scholar
• Csik V, Molnar J. Possible adverse interaction between clozapine and ampicillin in an adolescent with schizo phrenia. Journal of Child and Adolescent Psychopharmacology 1994; 4: 123–128
   Google Scholar
• Jackson C W, Markowitz J S, Brewerton T D. Delirium associated with clozapine and benzodiazepine combinations. Annals of Clinical Psychiatry 1995; 7: 139–141
   Google Scholar
• Miller D D. Effect of phenytoin on plasma clozapine con centrations in two patients. Journal of Clinical Psychiatry 1991; 52: 23–25
   PubMed Web of Science ®Google Scholar
• Raitasuo V, Lehtovaara R, Huttunen M O. Carbamazepine and plasma levels of clozapine. American Journal of Psychiatry 1993; 150: 169
   Google Scholar
• Tiihonen J., Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of antipsychotic drugs. Pharmopsychiatry 1995; 28: 26–28
   PubMed Web of Science ®Google Scholar
• Bachmann K A, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993; 23: 307–315
   PubMed Web of Science ®Google Scholar
• Jones C R, Lubet R A. Induction of a pleiotropic response by phenobarbital and related compounds. Response in various inbred strains of rats, response in various species and the induction of aldehyde dehydrogenase in Copenhagen rats. Biochemical Pharmacology 1992; 44: 1651–1660
   PubMedGoogle Scholar
• Funderburg L G, Vertrees J E, True J E, Miller A L, et al. Seizure after the addition of erythromycin to clozapine treatment. American Journal of Psychiatry 1994; 151: 1840–1841
   PubMed Web of Science ®Google Scholar
• Szymanski S, Lieberman J A, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. Journal of Clinical Psychiatry 1991; 52: 21–22
   PubMed Web of Science ®Google Scholar
• Sesardic D, Boobis A R, Edwards R J, Davies D S. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology 1988; 26: 363–372
   PubMed Web of Science ®Google Scholar
• Yonkers K A, Kando J C, Cole J O, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medications. American Journal of Psychiatry 1992; 149: 587–595
   PubMed Web of Science ®Google Scholar
• Bondesson V, Lindstrom L H. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology 1988; 95: 471–475
   Web of Science ®Google Scholar
• Jann M W, Grimsley S R, Gray E C, Chang W H. Pharmacokinetics and pharmacodynamics of clozapine. Clinical Pharmacokinetics 1993; 24: 161–176
   PubMed Web of Science ®Google Scholar
• Atkin K, Kendall F, Gould D, et al. Neutropenia and agran-ulocytosis in patients receiving clozapine in the UK, Ireland. British Journal of Psychiatry 1996; 169: 483–488
   PubMed Web of Science ®Google Scholar
• Alvir J, Ma J, Lieberman A J, Safferman A Z, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. New England Journal of Medicine 1993; 329: 162–167
   PubMed Web of Science ®Google Scholar
• Haller E, Binder R L. Clozapine and seizures. American Journal of Psychiatry 1990; 147: 1069–1071
   PubMed Web of Science ®Google Scholar
• Lieberman J A, Safferman A Z. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Quarterly 1992; 63: 51–70
   PubMedGoogle Scholar
• Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. British Journal of Psychiatry 1992; 160: 54–59
   Web of Science ®Google Scholar
• Thombeg S A, Ereshefsky L. Neuroleptic malignancy syndrome associated with clozapine monotherapy. Neuropharmacology 1993; 13: 510–514
   Google Scholar
• Chatterton R, Cardy S, Schramm T M. Neuroleptic malig nant syndrome and clozapine monotherapy. Australian and New Zealatid Journal of Psychiatry 1996; 30: 692–693
   PubMed Web of Science ®Google Scholar
• Lovdahl M J, Perry P J, Miller D D. The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Therapeutic Drng Monitoring 1991; 13: 69–72
   PubMed Web of Science ®Google Scholar
• Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human plasma using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography 1992; 583: 209–216
   PubMed Web of Science ®Google Scholar
• Freudenreich O, McEvoy J P, Cooper T B. Monitoring of clozapine blood levels in the real world. Journal of Clinical Psychopharmacology 1996; 16: 90–91
   Google Scholar
• Lieberman J A, Kane J M, Safferman A Z, et al. Predictors of response to clozapine. Journal of Clinical Psychiatry 1994; 55: 126–128
   PubMed Web of Science ®Google Scholar
• Pickar D, Owen R R, Litman R E, et al. Predictors of cloza pine response in schizophrenia. Journal of Clinical Psychiatry 1994; 55: 129–132
   Google Scholar
• Miller D. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizo phrenia. Annals of Clinical Psychiatry 1996; 8: 99–109
   Google Scholar
• Owen J A, Delva N J, Lawson J S. Clozapine concentrations and clinical response in schizophrenic patients. American Journal of Psychiatry 1992; 149: 1120–1121
   Google Scholar
• Perry J, Miller D. Clinical use of clozapine plasma concentrations. Clinical use of antipsychotic drug plasma levels, S Marder, J M Davis, P G Janicak. American Psychiatric Press, Washington, DC 1993; 85–99
   Google Scholar
• Gerson S, Arce C, Meltzer H. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. British Journal of Haematology 1994; 86: 555–561
   Google Scholar
• Nordin C, Alme B, Bondesson U. CSF and plasma concentrations of clozapine and its demethyl metabolite: a pilot study. Psychopharmacology Berlin 1995; 122: 104–107
   PubMed Web of Science ®Google Scholar